Evaluating the Immunogenicity of Antibody–drug Conjugates

Evaluating the Immunogenicity of Antibody–drug Conjugates

Strategies for Development and Validation of Neutralizing Antibody Assays Supporting Biosimilars

Clinical relevance of immunogenicity: an interview with Arno Kromminga

Exploratory biomarker testing: to qualify or validate the assay?

Immunogenicity Considerations for Antibody–drug Conjugates: A Focus on Neutralizing Antibody Assays

Bioanalysis Zone’s “Ask the Experts” Series on Biosimilars

Defining Best Practices for Biosimilar Development

Cell-Based Assays Keep Biosimilars on Track

Interview with Afshin Safavi (Founder & CSO, BioAgilytix) on biomarker analysis in support of preclinical and clinical studies

Meeting the rigorous demands of biosimilar pharmacokinetics

How to win client trust as a CRO

Running a successful CRO

How to set up a successful CRO by surrounding yourself with the right team members

Starting a CRO on personal credit

Parallelism and Matrix Interference: The Importance of Nomenclature (Part 1)

Growing Clinical Biomarker Assays

Development and validation of an alpha fetoprotein immunoassay using Gyros technology

Implementation of a universal analytical method in early-stage development of human antibody therapeutics

Validation of a Gyrolab™ assay for quantification of rituximab in human serum

Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis